Skip to main content
SpringerLink
Log in

Differences between antipsychotic drugs in persistence of brain levels and behavioral effects

  • Original Investigations
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

After a single dose of the butyrophenone neuroleptic haloperidol, behavioral effects and detectable drug levels in rat brain can last for several weeks. To determine if such persistence is a general property of neuroleptics, we compared drug levels and effects after IP administration of two butyrophenones (haloperidol and bromperidol), a high potency (fluphenazine) and a low potency (chlorpromazine) phenothiazine. Drug levels in brain tissue were measured by high pressure liquid chromatography and behavioral effects monitored as inhibition of apomorphine-induced stereotypy. Estimated near terminal elimination half-lives (t1/2) from brain for acutely administered chlorpromazine (20 mg/kg) and fluphenazine (1 mg/kg) were 0.41 and 0.62 days, respectively, and neither drug was detectable after 4 days. Fluphenazine given daily for 5 days showed an only slightly slower elimination (t1/2=1.1 days). In contrast, near-terminal elimination half-lives from brain for haloperidol and bromperidol (both at 1 mg/kg, IP) were much longer (6.6 and 5.8 days, respectively), and each was detectable for 21 days after dosing. Inhibition of apomorphine-induced stereotypy correlated highly (r=0.95) with brain levels of haloperidol. For fluphenazine, given once or repeatedly, early inhibition was replaced within 1 week by supersensitivity to apomorphine which persisted for up to 3 weeks. These findings, indicating marked differences in clearance and recovery times after dosing with butyrophenones and phenothiazines, have clear implications for studies of the effects of neuroleptic drugs in rats. While there are limits to the extrapolation of these findings to other species, our results and those from studies in human subjects suggest similarly persistent drug levels and effects may be seen when patients are withdrawn from neuroleptic drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Alphs LD, Lee HS (1991) Comparison of withdrawal of typical and atypical antipsychotic drugs: a case study. J Clin Psychiatry 52:346–348

    Google Scholar 

  • Antelman SM, Kocan D, Edwards EJ, Knopf S, Perel JM, Stiller R (1986) Behavioral effects of a single neuroleptic treatment grow with the passage of time. Brain Res 385:58–67

    Google Scholar 

  • Baldessarini RJ (1990) Drugs and treatment of psychiatric disorders. In: Gilman AG, Goodman LS, Rall TW, Murad F (eds) Goodman and Gilman's Pharmacologic basis of therapeutics, 8th edn. Pergamon Press, New York, pp 383–435

    Google Scholar 

  • Baldessarini RJ, Kula N, George T, Campbell, Bakthavachalam V, Neumeyer JL (1991) Recovery of central D1 and D2 receptors following alkylation in young and adult rat brain (Abs. 432.9). Neurosci Soc Abstr 17[2]:1091

    Google Scholar 

  • Caffey EM, Forrest IS, Frank TV, Klett CJ (1963) Phenothiazine excretion in chronic schizophrenics. Am J Psychiatry 120:578

    Google Scholar 

  • Cambon H, Baron JC, Boulenger JP, Loc'h C, Zarifian E, Maziere B (1987) In vivo asay for neuroleptic receptor binding in the striatum — positron tomography in humans. Br J Psychiatry 151:824–830

    Google Scholar 

  • Campbell A, Herschel M, Cohen BM, Baldessarini RJ (1980) Tissue levels of haloperidol by radioreceptor assay and behavioral effects of haloperidol in the rat. Life Sci 27:633–640

    Google Scholar 

  • Campbell A, Baldessarini RJ, Ram VJ, Neumeyer JL (1982) Behavioral effects of (-)10,11-methylenedioxy-N-n-propylnorapomorphine, an orally effective long-acting agent active at central dopamine receptors, and analagous aporphines. Neuropharmacology 21:953–961

    Google Scholar 

  • Campbell A, Baldessarini RJ, Kula NS (1985) Prolonged antidopamine actions of single doses of butyrophenones in the rat. Psychopharmacology 87:161–166

    Google Scholar 

  • Campbell A, Baldessarini RJ, Teicher MH (1988) Decreasing sensitivity to neuroleptic agents in developing rats; evidence for a pharmacodynamic factor. Psychopharmacology 94:46–51

    Google Scholar 

  • Carlsson A (1978) Antipsychotic drugs, neurotransmitters and schizophrenia. Am J Psychiatry 135:164–173

    Google Scholar 

  • Cohen BM, Zubenko GS (1985) In vivo effects of psychotropic agents on the physical properties of cell membranes in the rat brain. Psychopharmacology 86:365–368

    Google Scholar 

  • Cohen BM, Babb S, Campbell A, Baldessarini RJ (1988) Persistence of haloperidol in brain. Arch Gen Psychiatry 45:879–880

    Google Scholar 

  • Cohen BM, Baldessarini RJ, Campbell A, Tsuneizumi T, Babb SM (1991) Persistence of antipsychotic drug levels and effects. In: Tamminga CA, Schulz SC (eds) Advances in neuropsychiatry and psychopharmacology. Raven Press, New York, pp 277–284

    Google Scholar 

  • Creese I, Burt DR, Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192:481–483

    Google Scholar 

  • Curry SH, Marshall JHL, Davis JM, Janowsky DS (1970) Chlorpromazine plasma levels and effects. Arch Gen Psychiatry 22:189–196

    Google Scholar 

  • Dahl SG, Strandjord RE (1977) Pharmacokinetics of chlorpromazine after single and chronic dosage. Clin Pharmacol Ther 21:437–448

    Google Scholar 

  • Davidson M, Kahn RS, Powchik P, Warne P, Losonczy MF, Kaminsky R, Apter S, Jaff S, Davis KL (1991) Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation. Arch Gen Psychiatry 48:73–76

    Google Scholar 

  • Ereshefsky L, Jann MW, Saklad SR, Davis CM (1986) Bioavailability of psychotropic drugs: historical perspective and pharmacokinetic overview. J Clin Psychiatry 47 suppl [9]:6–15

    Google Scholar 

  • Farde L, Wiesel F-A, Halldin C, Sedvall G (1988) Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45:71–76

    Google Scholar 

  • Forsman A, Ohman R (1977) Applied pharmacokinetics of haloperidol in man. Curr Ther Res 21:396–411

    Google Scholar 

  • Hubbard JW, Ganes D, Midha KK (1987) Prolonged pharmacologic activity of neuroleptic drugs. Arch Gen Psychiatry 44:99–100

    Google Scholar 

  • Itoh H, Ohtsuka N, Ogita K, et al. (1977) Malignant neuroleptic syndrome: Its present state in Japan in clinical problems. Folia Psychiatr Neurol Japonica 31:565–576

    Google Scholar 

  • Javaid JI, Sharma RP, Janicak PG, Davis JM (1990) Plasma HVA in psychiatric patients: longitudinal studies. Psychopharmacol Bull 26:361–365

    Google Scholar 

  • Johnson PC, Charalampous KD, Braun GA (1967) Absorption and excretion and tritiated haloperidol in man (a preliminary report). Int J Neuropsychiatry 3[suppl]1:524–525

    Google Scholar 

  • Kirch D, Hattox S, Bell J, Murphy R, Freedman R (1983) Plasma homovanillic acid and tardive dyskinesia during neuroleptic maintenance and withdrawal. Psychiatry Res 9:217–223

    Google Scholar 

  • Korpi ER, Phelps BH, Granger H, Chang W-H, Linnoila M, Meek VL, Wyatt RJ (1983) Simultaneous determination of haloperidol and its reduced metabolite in serum and plasma by isocratic liquid chromatography with electrochemical detection. Clin Chem 29:624–628

    Google Scholar 

  • Korpi ER, Kleinman JE, Costakos DT, Linnoila M, Wyatt RJ (1984) Reduced haloperidol in the post-mortem brains of haloperidol-treated patients. Psychiatry Res 11:259–268

    Google Scholar 

  • Korpi ER, Costakos DT, Wyatt RJ (1985) Interconversions of haloperidol and reduced haloperidol in guinea pig and rat liver microsomes. Biochem Pharmacol 34:2923–2927

    Google Scholar 

  • Kurland AA, Huang CL, Hallam KJ, Hanlon TE (1965) Further studies of chlorpromazine metabolism and relapse rate. J Psychiatr Res 3:27–35

    Google Scholar 

  • Levine J, Schooler NR, Severe J, Escobar J, Gelenberg A, Mandel M, Sovner R, Steinbook R (1980) Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study. In: Cattabeni F et al (eds) Long-term effects of neuroleptics. Raven Press, New York, pp 483–493

    Google Scholar 

  • Lewi PJ, Heykants JJP, Allewijn FTN, Dony JGH, Janssen PAJ (1970) Distribution and metabolism of neuroleptic drugs. Arzneimittelforschung (Drug Res) 20:943–948

    Google Scholar 

  • Lutz EG (1965) Dissipation of phenothiazine effect and recurrence of schizophrenic psychosis. Dis Nerv Syst 26:355–357

    Google Scholar 

  • Midha KK, Hawes EM, Hubbard JW, Korchinski ED, McKay G (1988) Variation in the single dose pharmacokinetics of fluphenazine in psychiatric patients. Psychopharmacology 96:206–211

    Google Scholar 

  • Muller P, Seeman P (1978) Dopaminergic supersensitivity after neuroleptics: time-course and specificity. Psychopharmacology 60:1–11

    Google Scholar 

  • Ohman R, Larsson M, Nilsson IM, Engel J, Carlsson A (1977) Neurometabolic and behavioral effects of haloperidol in relation to drug level in serum and brain. Naunyn-Schmiedeberg's Arch Pharmacol 299:105–114

    Google Scholar 

  • Pich EM, Benfenati F, Farabegoli C, Fuxe K, Meller E, Aronsson M, Goldstein M, Agnati LF (1987) Chronic haloperidol affects striatal D2-dopamine receptor reappearance after irreversible receptor blockade. Brain Res 435:147–152

    Google Scholar 

  • Pickar D, Labarca R, Doran AR, Wolkowitz OM, Roy A, Breier A, Linnoila M, Paul SM (1986) Longitudinal measurement of plasma homovanillic acid levels in schizophrenia patients. Arch Gen Psychiatry 43:669–676

    Google Scholar 

  • Sakalis G, Curry SH, Mould GP, Lader MH (1972) Physiologic and clinical effects of chlorpromazine and their relationship to plasma level. Clin Pharmacol Ther 13:931–946

    Google Scholar 

  • Seeman P (1977) Anti-schizophrenic drugs — membrane receptor sites of action. Biochem Pharmacol 26:1741–1748

    Google Scholar 

  • Sramek J, Herrera J, Costa J, Heh C (1987) Persistence of plasma neuroleptic levels after drug discontinuation. J Clin Psychopharmacol 7:436–437

    Google Scholar 

  • Stoll AL, Baldessarini RJ, Cohen BM, Finklestein SP (1984) Assay of plasma thioridazine and metabolites by high-performance liquid chromatography with amperometric detection. J Chromatogr Biomed Applic 307:457–463

    Google Scholar 

  • Sunderland T, Cohen BM (1987) Blood to brain distribution of neuroleptics. Psychiatry Res 20:299–305

    Google Scholar 

  • Sved S, Perales A, Palaic D (1971) Chlorpromazine metabolism in chronic schizophrenics. Br J Psychiatry 119:589–596

    Google Scholar 

  • Svendsen CN, Bird ED (1986) HPLC with electrochemical detection to measure chlorpromazine, thioridazine and metabolites in human brain. Psychopharmacology 90:316–321

    Google Scholar 

  • Volavka J, Cooper TB (1987) Review of haloperidol blood level and clinical response: looking through the window. J Clin Psychopharmacol 7:25–30

    Google Scholar 

  • Xu S, Hatada Y, Black LE, Creese I, Sibley DR (1991) N-(p-Isothiocycanatophenethyl)spiperone, a selective and irreversible antagonist of D2 dopamine receptors in brain. J Pharmacol Exp Ther 257:608–615

    Google Scholar 

  • Zetler G, Baumann GH (1985) Pharmacokinetics and effects of haloperidol in the isolated mouse. Pharmacology 31:318–327

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mailman Research Center, McLean Hospital, 115 Mill Street, 02178, Belmont, MA, USA

    Bruce M. Cohen, Tomohiro Tsuneizumi, Ross J. Baldessarini, Alexander Campbell & Suzann M. Babb

Authors
  1. Bruce M. Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tomohiro Tsuneizumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ross J. Baldessarini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alexander Campbell
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Suzann M. Babb
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cohen, B.M., Tsuneizumi, T., Baldessarini, R.J. et al. Differences between antipsychotic drugs in persistence of brain levels and behavioral effects. Psychopharmacology 108, 338–344 (1992). https://doi.org/10.1007/BF02245121

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02245121

Key words

Search

Navigation